Sofosbuvir (PSI-7977, GS-7977)
Molecular Weight(MW): 529.45
Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
1 Customer Review
Inhibition of hepatitis C virus by sofosbuvir. (A) Determination of 50% cytotoxic concentration (CC50). Huh-7.5 reporter cells (1.3×104) were incubated with the indicated concentration of sofosbuvir (SOF) during 72 h at 37°C, and the numbers of viable cells were counted using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. (B) Determination of the drug concentration required for 50% inhibition (IC50) of infectious HCV yield. Huh-7.5 reporter cells (1.0×105) were infected with 3 103 TCID50 of HCV p0 in the presence of the indicated concentrations of SOF. Virus titers were determined in the cell culture supernatants at 72 h postinfection. Viral titers are given as the percentages of the titers obtained in the infection in the absence of SOF. (C) Progeny production in the course of three serial passages of HCV p0 in the presence of increasing concentrations of SOF, as indicated. Infection conditions are those explained in the description of panel B. Procedures are detailed in Materials and Methods.
Antimicrob Agents Chemother, 2016, 60(6):3786-3793.. Sofosbuvir (PSI-7977, GS-7977) purchased from Selleck.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
Click to view more
2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
|Description||Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.|
As HCV NS5B polymerase inhibitor, PSI-7977 displays more potent inhibitory activity against HCV RNA replication than PSI-7976 with EC50 of 92 nM versus 1.07 μM and EC90 of 0.29 μM versus 2.99 μM, consistent with that incubating clone A cells with PSI-7977 leads to a higher concentration of PSI-7409 than clone A cells incubated with PSI-7976. PSI-7977 is an effective substrate for CatA to form PSI-352707 with 18-30 fold more potency as compared with PSI-7976. Unlike GS-7976, however, the CES1-mediated hydrolysis of PSI-7977 does not progress in a time-dependent manner.  The S282T NS5B polymerase mutation but not S96T mutation confers resistance to PSI-7977 with EC90 increases from 0.42 μM to 7.8 μM. When assessed in an 8-day cytotoxicity assay, PSI-7977 displays no cytotoxicity against Huh7, HepG2, BxPC3, and CEM cells even at concentrations up to 100 μM. PSI-7977 treatment for 14 days shows a IC90 of 72.1 μM and 68.6 μM for the inhibition of mtDNA and rDNA, respectively, in HepG2 cells.  PSI-7977 exhibits potent activity against genotype (GT) 1a, 1b, and 2a (strain JFH-1) replicons and chimeric replicons containing GT 2a (strain J6), 2b, and 3a NS5B polymerase. Sequence analysis of the JFH-1 NS5B region indicates that additional amino acid changes including T179A, M289L, I293L, M434T, and H479P are selected both prior to and after the emergence of S282T, which are required to confer resistance to PSI-7977. 
|In vitro||DMSO||100 mg/mL (188.87 mM) warming|
|Ethanol||100 mg/mL (188.87 mM)|
|Water||11 mg/mL warmed (20.77 mM)|
* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02339038||Active, not recruiting||HCV HIV||National Institutes of Health Clinical Center (CC)||January 7, 2015||Phase 4|
|NCT02985281||Enrolling by invitation||Pharmacological Action||National Liver Institute, Egypt|Pharco Pharmaceuticals||December 2016||Phase 2|Phase 3|
|NCT02992457||Recruiting||Hepatitis C||Tanta University||December 2016||Phase 4|
|NCT02858180||Recruiting||Hepatitis C, Chronic|Heart Failure|Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial||Duke University|Gilead Sciences||December 2016||Phase 4|
|NCT02939989||Enrolling by invitation||Hepatitis C Virus Infection||AbbVie||November 2016||Phase 3|
|NCT02959359||Not yet recruiting||Hepatocellular Carcinoma||Taipei Veterans General Hospital, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital|China Medical University Hospital|Chi Mei Medical Hospital|Chiayi Christian Hospital|National Taiwan University Hospital|Chang Gung Memorial Hospital|Tri-Service General Hospital|National Cheng-Kung University Hospital||November 2016||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.